 |
|
Neonatal Risks of Maternal Treatment With Mood Stabilizers
Mark Olfson, MD, MPH;
Steven Marcus, PhD
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
Several of the drugs used to treat bipolar disorder are known teratogens.1 Maternal treatment with valproate sodium,2 carbamazepine,3 and lithium4 are each associated with an increased risk of major congenital abnormalities.
In their recent study of maternal antidepressant treatment and neonatal outcomes, Oberlander and colleagues5 report that prenatal selective serotonin reuptake inhibitor (SSRI) exposure is associated with an increased risk of neonatal low birth weight and respiratory distress. The authors compare neonates born of mothers who received SSRIs during their pregnancies with those of depressed pregnant women who did not receive antidepressants. Although neither group of women received benzodiazepines or antipsychotic medications during their pregnancy, women treated with mood stabilizers were not excluded from the study. Because pregnant mothers treated with SSRIs are presumably more likely to receive mood stabilizers than those who are not treated with antidepressants, it is possible that in . . . [Full Text of this Article]
AUTHOR INFORMATION
RELATED LETTER
Neonatal Risks of Maternal Treatment With Mood Stabilizers—Reply
Tim F. Oberlander, William Warburton, Shaila Misri, Jaafar Aghajanian, and Clyde Hertzman
Arch Gen Psychiatry. 2007;64(7):867-868.
EXTRACT
| FULL TEXT
RELATED ARTICLE
Neonatal Outcomes After Prenatal Exposure to Selective Serotonin Reuptake Inhibitor Antidepressants and Maternal Depression Using Population-Based Linked Health Data
Tim F. Oberlander, William Warburton, Shaila Misri, Jaafar Aghajanian, and Clyde Hertzman
Arch Gen Psychiatry. 2006;63(8):898-906.
ABSTRACT
| FULL TEXT
|
